



May 13, 2025

JCR Pharmaceuticals Co., Ltd.

Translation

Notice of Recognition of Gain on Deferred Income Taxes

Hyogo, Japan – May 13, 2025 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”) hereby announces that we have recorded the following income tax adjustments for the consolidated fiscal year ended March 31, 2025.

1. Recognition of Gain on Deferred Income Taxes

Based on our performance trends for the fiscal year ended March 31, 2025 and beyond, and after carefully reviewing the recoverability of deferred tax assets, including a review of the company's classification under the "Application Guidance on the Recoverability of Deferred Tax Assets," we have decided to recognize additional deferred tax assets with recoverable value. Consequently, we have recognized a corporate tax adjustment (profit) of 1,771 million yen in our consolidated financial results for the fiscal year ended March 31, 2025.

2. Impact on business results

The above information is reflected in the “Financial Report for the Year Ended March 31, 2025 (FY2024) [J-GAAP] (Consolidated)” released today.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit.

<https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on

judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###